Topigen - Home Page


Français
»Mission Topigen uses its expertise in respiratory disease research and proprietary gene-based therapies to create novel, synergistic and cost-effective topical products for asthma, COPD, allergic rhinitis and associated conditions with unmet therapeutic needs for the global marketplace.

	Our Therapeutic Focus Asthma TPI ASM8 is a multitargeted compound which effectively blocks two major arms of the inflammatory response in asthma. More » COPD TPI 1020 and TPI 1100 are two compounds being developed for the treatment of COPD. More » Allergic Rhinitis TPI ARL8, a compound with the same mechanism of action as TPI ASM8, is being studied in allergic rhinitis. More »	News 2008-08-14 Topigen Pharmaceuticals appoints Mark Parry-Billings, Ph.D., as Chief Executive Officer More » 2008-07-23 Topigen Pharmaceuticals completes enrollment of Phase II clinical study of TPI ASM8 in asthma More » 2008-06-19 Topigen Pharmaceuticals presents at BIO 2008 in San Diego. Click to view Corporate Presentation »	AllerGen-Topigen Industrial Research and Development Fellowship AllerGen NCE Inc., the Allergy, Genes and Environment Network and Topigen offer a post-doctoral position in industrial research and development - an opportunity to work for two years at Topigen's facility in Montreal, Quebec. Applications deadline September 1, 2008. Click here for details on how to apply: www.AllerGen-nce.ca.
	Copyright © 2005-2008, Topigen Pharmaceuticals Inc. All rights reserved. Terms of Use.